Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 50 versus DEXTROSE 70 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 50 versus DEXTROSE 70 IN PLASTIC CONTAINER.
DEXTROSE 50% vs DEXTROSE 70% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous administration of 50% dextrose solution rapidly elevates blood glucose levels by providing exogenous glucose, which is taken up by cells via glucose transporters and metabolized to produce adenosine triphosphate (ATP), thereby correcting hypoglycemia.
Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose concentration and is metabolized to carbon dioxide and water, yielding energy.
For hypoglycemia: 25 grams (50 mL of 50% solution) intravenous bolus, may repeat once if needed. For insulin-induced hypoglycemia: 25-50 grams intravenously.
Adults: Intravenous infusion, dose dependent on clinical need; typically 500 mL of 70% dextrose (350 g) administered as part of parenteral nutrition at a rate not exceeding 0.5 g/kg/h.
None Documented
None Documented
2-4 hours (exogenous glucose); in critically ill patients or hyperglycemic states, half-life may be prolonged due to impaired glucose utilization.
30-60 minutes; clinically relevant in hyperglycemic states or renal impairment where glucose clearance is prolonged
Primarily eliminated by cellular metabolism to carbon dioxide and water; renal excretion of unchanged glucose occurs when plasma concentration exceeds renal threshold (approximately 180 mg/dL), accounting for <5% of elimination under normoglycemic conditions.
100% renal; metabolized to CO2 and water; none excreted unchanged under normal conditions
Category C
Category C
Intravenous Hypertonic Dextrose Solution
Intravenous Hypertonic Dextrose Solution